ConforMIS, which sells customized knee replacement implants, announced terms for its IPO on Thursday.
The Bedford, MA-based company plans to raise $135 million by offering 9.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, ConforMIS would command a fully diluted market value of $644 million.
ConforMIS has raised over $240 million in private funding, including a $50 million Series D round led by Aeris Capital in 2009 and over $190 million from Series E preferred shares. Primary shareholders include Aeris Capital, Abu Dhabi Investment Authority, Milestone Management, founder and CEO Philipp Lang, Xeraya Capital and Abu Dhabi Investment Council.
ConforMIS, which was founded in 2004 and booked $52 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol CFMS. J.P. Morgan and Deutsche Bank are the joint bookrunners on the deal. It is expected to price during the week of June 29, 2015.
